Subtype
Esophageal Squamous Cell Carcinoma
CI-CAN-00002629ESCCExplore in graph →
212 active trials3 approved drugs7 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002629ESCCExplore in graph →
Clinical trials
555 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (35)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07049185 | QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma(QICE-ESCC) | not yet recruiting | Phase 2 | 35 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jun 13, 2025 |
| clinicaltrials |
| NCT04548440 | Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients | completed | Phase 2 | 50 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT07016724 | Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer | recruiting | Phase 2 | 208 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06446726 | Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Sichuan UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06988956 | Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 95 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04666090 | Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 42 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06861894 | Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC | not yet recruiting | Phase 2 | 164 | Zhigang LiOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06908382 | Neoadjuvant QL1706 Therapy for ESCC | recruiting | Phase 2 | 32 | Shandong Provincial HospitalOTHER_GOV | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06637163 | Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC | recruiting | Phase 2 | 100 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06843889 | A Phase II Study of Toripalimab Combined With Sequential Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 34 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06907602 | Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma(ONTRESCC) | recruiting | Phase 2 / Phase 3 | 120 | Peking Union Medical College HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06903871 | Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) | not yet recruiting | Phase 2 | 190 | Hebei Medical University Fourth HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06861777 | Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 / Phase 3 | 474 | YIN LIOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | terminated | Phase 2 | 205 | Seagen Inc.INDUSTRY | 6 | Mar 10, 2025 | clinicaltrials |
| NCT06852456 | QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Feb 28, 2025 | clinicaltrials |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 10 | Peking UniversityOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT04732494 | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(AdvanTIG-203) | completed | Phase 2 | 125 | BeiGeneINDUSTRY | 6 | Jan 31, 2025 | clinicaltrials |
| NCT06489197 | AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT05214222 | Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma(ANSWER) | recruiting | Phase 2 | 100 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06746961 | Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy | not yet recruiting | Phase 1 / Phase 2 | 49 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT04212598 | The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer | completed | Phase 2 | 40 | Wuhan UniversityOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT06603402 | Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC | recruiting | Phase 2 | 41 | Sichuan UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06709417 | A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) | recruiting | Phase 2 | 52 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02647125 | A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC | completed | Phase 2 | 126 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06703047 | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 180 | Fudan UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT05520619 | Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)(EC-CRT-002) | active not recruiting | Phase 2 | 114 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT02844075 | Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29) | completed | Phase 2 | 28 | Yonsei UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06691503 | A Clinical Trial of Esophagectomy for Esophageal Carcinoma | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT03985046 | Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC | completed | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04721223 | JAB-3068 Activity in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 12 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06588335 | BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 20 | Henan Provincial People's HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06599775 | Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer | not yet recruiting | Phase 2 | 42 | Shanghai Zhongshan HospitalOTHER | 0 | Sep 19, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06508229 | Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC | not yet recruiting | Phase 2 | 65 | Harbin Medical UniversityOTHER | 0 | Jul 18, 2024 | clinicaltrials |
| NCT06354140 | PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY | recruiting | Phase 2 | 45 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT04839471 | BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)(BEAR) | completed | Phase 2 | 49 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06487702 | A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 70 | Rui-hua Xu, MD, PhDOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04435197 | Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma(PALACE-2) | completed | Phase 2 | 143 | Ruijin HospitalOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06468644 | Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 60 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06468670 | Short-course Radiotherapy Combined With Sintilimab for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 21, 2024 | clinicaltrials |
| NCT06463834 | A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06342167 | Efficacy and Safety of Concurrent PD-1 Inhibitor and Radiotherapy With Immunonutrition for Esophageal Squamous Cell Carcinoma | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 11, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 3, 2025source: clinicaltrials